Exchange: NASDAQ·Updated 07:34 PM EDT

ALDX News

News
all
press releases
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
More News
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Zacks
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Zacks
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
Zacks
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
Zacks
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
Zacks
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
Zacks
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
Zacks
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
Zacks
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.
Zacks

Advertisement|Remove ads.